Trial Profile
A Comparative Study Efficacy of Trametinib (CT) in Comparison With Trametinib (MEKINIST) in Patients With BRAF V600E or V600K Mutation-positive Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Sep 2015
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 13 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 03 Apr 2015 New trial record